Cronos Group (TSX:CRON) has drawn fresh attention after President Donald Trump publicly supported Medicare coverage for CBD, a first for any sitting U.S. president. The sector-wide rally reflected renewed optimism among cannabis investors.
See our latest analysis for Cronos Group.
Momentum around Cronos Group has been rebounding, supported by a sector-wide cannabis surge and the company’s addition to the S&P Global BMI Index. While short-term share price returns have been modest, the recent rally highlights renewed investor interest. The company’s long-term total shareholder returns reflect the ups and downs typical of the cannabis space, with a 1-year positive return but heavier three- and five-year declines.
If Cronos’s recent moves have you wondering what else the market is rewarding, it could be the right moment to broaden your investing radar and discover fast growing stocks with high insider ownership
But with Cronos…
